Batoclimab (RVT-1401) is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn) with high affinity for the IgG-binding site on FcRn, and by competitively binding to this site, Batoclimab effectively blocks FcRn-mediated recycling of immunoglobulin G (IgG), resulting in the enhanced degradation of IgG and subsequent reductions in circulating IgG levels, making it a candidate compound for research in autoimmune diseases such as myasthenia gravis and thyroid eye disease.